SK116894A3 - Mixture for treatment of fibrotic disordes - Google Patents

Mixture for treatment of fibrotic disordes Download PDF

Info

Publication number: SK116894A3
Authority: SK; Slovakia
Prior art keywords: beta; ftr; composition; factor; wound
Prior art date: 1992-03-28

Application number

SK1168-94A

Other languages

English (en)

Slovak (sk)

Inventor

Mark W J Ferguson

Mamta Shah

Original Assignee

Univ Manchester

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-28

Filing date

1993-03-22

Publication date

1995-02-08

1993-03-22 Application filed by Univ Manchester filed Critical Univ Manchester

1995-02-08 Publication of SK116894A3 publication Critical patent/SK116894A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 40
230000003176 fibrotic effect Effects 0.000 title abstract description 4
239000003102 growth factor Substances 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims abstract description 9
230000035876 healing Effects 0.000 claims abstract description 7
239000003937 drug carrier Substances 0.000 claims abstract description 5
208000027418 Wounds and injury Diseases 0.000 claims description 80
206010052428 Wound Diseases 0.000 claims description 72
230000015572 biosynthetic process Effects 0.000 claims description 22
210000001519 tissue Anatomy 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 13
239000007924 injection Substances 0.000 claims description 13
238000002347 injection Methods 0.000 claims description 13
210000003041 ligament Anatomy 0.000 claims description 13
102000008186 Collagen Human genes 0.000 claims description 12
108010035532 Collagen Proteins 0.000 claims description 12
229920001436 collagen Polymers 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
206010016654 Fibrosis Diseases 0.000 claims description 9
230000003510 anti-fibrotic effect Effects 0.000 claims description 9
210000002808 connective tissue Anatomy 0.000 claims description 9
230000006378 damage Effects 0.000 claims description 8
230000004761 fibrosis Effects 0.000 claims description 8
208000014674 injury Diseases 0.000 claims description 8
102000005962 receptors Human genes 0.000 claims description 8
230000012010 growth Effects 0.000 claims description 7
102000004190 Enzymes Human genes 0.000 claims description 6
108090000790 Enzymes Proteins 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 6
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
229940126864 fibroblast growth factor Drugs 0.000 claims description 5
239000000443 aerosol Substances 0.000 claims description 4
239000006071 cream Substances 0.000 claims description 4
239000000499 gel Substances 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
230000002779 inactivation Effects 0.000 claims description 4
229920000642 polymer Polymers 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
239000002243 precursor Substances 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
230000005855 radiation Effects 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
238000002604 ultrasonography Methods 0.000 claims description 4
208000037816 tissue injury Diseases 0.000 claims description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
102000004954 Biglycan Human genes 0.000 claims description 2
108090001138 Biglycan Proteins 0.000 claims description 2
102000004237 Decorin Human genes 0.000 claims description 2
108090000738 Decorin Proteins 0.000 claims description 2
108091034117 Oligonucleotide Proteins 0.000 claims description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
239000002250 absorbent Substances 0.000 claims description 2
230000002745 absorbent Effects 0.000 claims description 2
239000013543 active substance Substances 0.000 claims description 2
102000023732 binding proteins Human genes 0.000 claims description 2
108091008324 binding proteins Proteins 0.000 claims description 2
229920001222 biopolymer Polymers 0.000 claims description 2
238000003776 cleavage reaction Methods 0.000 claims description 2
230000003111 delayed effect Effects 0.000 claims description 2
238000005538 encapsulation Methods 0.000 claims description 2
229920002674 hyaluronan Polymers 0.000 claims description 2
229960003160 hyaluronic acid Drugs 0.000 claims description 2
239000007943 implant Substances 0.000 claims description 2
238000002513 implantation Methods 0.000 claims description 2
238000011065 in-situ storage Methods 0.000 claims description 2
108020004999 messenger RNA Proteins 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
230000007017 scission Effects 0.000 claims description 2
239000008174 sterile solution Substances 0.000 claims description 2
230000009466 transformation Effects 0.000 claims description 2
238000011144 upstream manufacturing Methods 0.000 claims description 2
230000002262 irrigation Effects 0.000 claims 2
238000003973 irrigation Methods 0.000 claims 2
206010057254 Connective tissue inflammation Diseases 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
210000003705 ribosome Anatomy 0.000 claims 1
239000000243 solution Substances 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 2
208000035475 disorder Diseases 0.000 abstract 1
108091007054 readthrough proteins Proteins 0.000 description 125
230000003472 neutralizing effect Effects 0.000 description 12
210000002540 macrophage Anatomy 0.000 description 11
102000016359 Fibronectins Human genes 0.000 description 10
108010067306 Fibronectins Proteins 0.000 description 10
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
210000002744 extracellular matrix Anatomy 0.000 description 9
230000001965 increasing effect Effects 0.000 description 8
210000001616 monocyte Anatomy 0.000 description 8
230000008595 infiltration Effects 0.000 description 7
238000001764 infiltration Methods 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
230000021953 cytokinesis Effects 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
238000004820 blood count Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
231100000241 scar Toxicity 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
230000036573 scar formation Effects 0.000 description 3
230000037390 scarring Effects 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
108091071247 Beta family Proteins 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
208000019428 Ligament disease Diseases 0.000 description 1
206010061223 Ligament injury Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940041682 inhalant solution Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Dermatology (AREA)
Marine Sciences & Fisheries (AREA)
Cell Biology (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK1168-94A 1992-03-28 1993-03-22 Mixture for treatment of fibrotic disordes SK116894A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929206861A GB9206861D0 (en)	1992-03-28	1992-03-28	Wound healing and treatment of fibrotic disorders
PCT/GB1993/000586 WO1993019769A1 (en)	1992-03-28	1993-03-22	Wound healing and treatment of fibrotic disorders

Publications (1)

Publication Number	Publication Date
SK116894A3 true SK116894A3 (en)	1995-02-08

Family

ID=10713078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1168-94A SK116894A3 (en)	1992-03-28	1993-03-22	Mixture for treatment of fibrotic disordes

Country Status (19)

Country	Link
US (1)	US6331298B1 (cs)
EP (1)	EP0646012B1 (cs)
JP (2)	JP3919212B2 (cs)
AT (1)	ATE230605T1 (cs)
AU (1)	AU673161B2 (cs)
BR (1)	BR9306226A (cs)
CA (1)	CA2131383C (cs)
CZ (1)	CZ236694A3 (cs)
DE (1)	DE69332624T2 (cs)
DK (1)	DK0646012T3 (cs)
ES (1)	ES2189790T3 (cs)
GB (1)	GB9206861D0 (cs)
HU (1)	HUT68905A (cs)
NO (1)	NO943466D0 (cs)
NZ (1)	NZ249937A (cs)
PT (1)	PT646012E (cs)
RU (1)	RU94042387A (cs)
SK (1)	SK116894A3 (cs)
WO (1)	WO1993019769A1 (cs)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
US7384634B2 (en) *	1991-08-30	2008-06-10	University Of South Florida	Connective tissue growth factor
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US5449671A (en) *	1993-09-29	1995-09-12	Alcon Laboratories, Inc.	Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5411940A (en) *	1993-09-29	1995-05-02	Alcon Laboratories, Inc.	Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
CA2149657A1 (en) *	1993-09-29	1995-04-06	Billie M. York	Compositions containing growth factors and antiplastic agents
WO1995026203A1 (en) *	1994-03-29	1995-10-05	The Victoria University Of Manchester	Wound healing
GB2288118A (en) *	1994-03-29	1995-10-11	Univ Manchester	Wound healing composition
US5621093A (en) *	1995-06-06	1997-04-15	Anika Research, Inc.	Steam-sterilizing solid hyaluronic acid
GB2304045A (en) *	1995-08-04	1997-03-12	Univ Manchester	Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) *	1995-08-09	1997-03-12	Univ Manchester	Pharmaceutical compositions containing cytokines
GB2306481A (en) *	1995-10-21	1997-05-07	Univ Manchester	Pharmaceutical comprising a stimulator of activin and/or inhibin
PT941108E (pt)	1996-12-04	2003-01-31	Renovo Ltd	Cicatrizacao de feridas e tratamento da fibrose
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP1740615B1 (en)	2004-03-31	2014-11-05	Genentech, Inc.	Humanized anti-tgf-beta antibodies
US8017395B2 (en)	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
AU2006202209B2 (en) *	2005-05-27	2011-04-14	Lifescan, Inc.	Amniotic fluid derived cells
JP2009500297A (ja) *	2005-06-08	2009-01-08	セントカー・インコーポレーテツド	眼の変性についての細胞療法
GB0514262D0 (en) *	2005-07-12	2005-08-17	Renovo Ltd	Promotion of epithelial regeneration
US20070122448A1 (en) *	2005-11-28	2007-05-31	Alireza Rezania	Compositions and methods to create a vascularized environment for cellular transplantation
GB0604964D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Protein folding
GB0604966D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
GB0604938D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Proteins, nucleic acids and medicaments
AU2007244675A1 (en)	2006-04-28	2007-11-08	Lifescan, Inc.	Differentiation of human embryonic stem cells
US8741643B2 (en)	2006-04-28	2014-06-03	Lifescan, Inc.	Differentiation of pluripotent stem cells to definitive endoderm lineage
GB0617816D0 (en) *	2006-09-11	2006-10-18	Renovo Ltd	Nucleic acids and methods of protein expression
EP2091557A2 (en)	2006-11-15	2009-08-26	Coda Therapeutics, INC.	Improved methods and compositions for wound healing
CA2676044C (en) *	2007-01-30	2019-10-22	University Of Georgia Research Foundation, Inc.	Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US9080145B2 (en) *	2007-07-01	2015-07-14	Lifescan Corporation	Single pluripotent stem cell culture
EP2559756B1 (en)	2007-07-01	2019-12-18	Janssen Biotech, Inc.	Single pluripotent stem cell culture
WO2009007848A2 (en) *	2007-07-12	2009-01-15	Compugen Ltd.	Bioactive peptides and method of using same
EP3957716A1 (en)	2007-07-18	2022-02-23	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
DK2185693T3 (da)	2007-07-31	2019-09-23	Lifescan Inc	Differentiering af humane embryoniske stamceller
CA2954431C (en)	2007-11-27	2021-08-24	Lifescan, Inc.	Differentiation of human embryonic stem cells to pancreatic cells
JP2011507599A (ja)	2007-12-21	2011-03-10	コーダセラピューティクス，インコーポレイテッド	改良医療デバイス
CA2710375A1 (en) *	2007-12-21	2009-07-09	Coda Therapeutics, Inc.	Treatment of orthopedic conditions
AU2008343758A1 (en) *	2007-12-21	2009-07-09	Coda Therapeutics, Inc.	Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
JP5733986B2 (ja)	2008-02-21	2015-06-10	ヤンセンバイオテツク，インコーポレーテツド	細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8623648B2 (en)	2008-04-24	2014-01-07	Janssen Biotech, Inc.	Treatment of pluripotent cells
EP2942392B1 (en)	2008-06-30	2018-10-03	Janssen Biotech, Inc.	Differentiation of pluripotent stem cells
MX2011000131A (es) *	2008-07-07	2011-05-10	Medidom Lab	Vendaje para sanacion de heridas, reductor de temperatura.
AU2009274517B2 (en)	2008-07-25	2015-03-26	The University Of Georgia Research Foundation, Inc.	Compositions for Mesoderm derived ISL1+ Multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
US20110305672A1 (en)	2008-07-25	2011-12-15	University Of Georgia Research Foundation, Inc.	COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20100028307A1 (en) *	2008-07-31	2010-02-04	O'neil John J	Pluripotent stem cell differentiation
EP2350265B1 (en)	2008-10-31	2019-04-17	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
US9234178B2 (en)	2008-10-31	2016-01-12	Janssen Biotech, Inc.	Differentiation of human pluripotent stem cells
KR101687344B1 (ko) *	2008-11-20	2016-12-16	얀센 바이오테크 인코포레이티드	평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
KR101774546B1 (ko)	2008-11-20	2017-09-04	얀센 바이오테크 인코포레이티드	마이크로-캐리어 상의 만능 줄기 세포 배양
CN103952372B (zh) *	2009-07-20	2016-10-05	詹森生物科技公司	人胚胎干细胞的分化
US8785184B2 (en)	2009-07-20	2014-07-22	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
CN102482643B (zh)	2009-07-20	2016-06-29	詹森生物科技公司	人胚胎干细胞的分化
PL2494035T3 (pl) *	2009-10-29	2018-07-31	Janssen Biotech, Inc.	Pluripotencjalne komórki macierzyste
DE202009017772U1 (de) *	2009-12-10	2011-04-21	Orthogen Ag	Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
SG10201408552YA (en)	2009-12-23	2015-02-27	Janssen Biotech Inc	Differentiation of human embryonic stem cells
CN102712902B (zh)	2009-12-23	2019-01-08	詹森生物科技公司	人胚胎干细胞的分化
PH12012501686A1 (en)	2010-03-01	2020-10-19	Janssen Biotech Inc	Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru)	2010-05-12	2016-06-20	Янссен Байотек, Инк.	Дифференцирование эмбриональных стволовых клеток человека
KR20190027969A (ko)	2010-08-12	2019-03-15	얀센 바이오테크 인코포레이티드	췌장 내분비 전구 세포를 이용한 당뇨병의 치료
PL2853589T3 (pl)	2010-08-31	2018-05-30	Janssen Biotech, Inc	Różnicowanie ludzkich zarodkowych komórek macierzystych
CN103154237B (zh)	2010-08-31	2016-03-16	詹森生物科技公司	多能干细胞的分化
EP3372672A1 (en)	2010-08-31	2018-09-12	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
EP2652125B1 (en)	2010-12-15	2017-04-26	Kadimastem Ltd.	Insulin producing cells derived from pluripotent stem cells
FI2794857T3 (fi)	2011-12-22	2026-03-25	Janssen Biotech Inc	Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en)	2012-03-07	2013-09-12	Janssen Biotech, Inc.	Defined media for expansion and maintenance of pluripotent stem cells
EP3450544A1 (en)	2012-06-08	2019-03-06	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells into pancreatic endodrine cells
BR112015015714A2 (pt)	2012-12-31	2017-07-11	Janssen Biotech Inc	suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
ES2837763T3 (es)	2012-12-31	2021-07-01	Janssen Biotech Inc	Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
US10370644B2 (en)	2012-12-31	2019-08-06	Janssen Biotech, Inc.	Method for making human pluripotent suspension cultures and cells derived therefrom
DK2938723T3 (da)	2012-12-31	2023-02-20	Janssen Biotech Inc	Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
US12558316B2 (en)	2013-03-13	2026-02-24	University Of Miami	Methods and compositions for the treatment of epidermolysis bullosa
WO2014159662A1 (en)	2013-03-13	2014-10-02	University Of Miami	Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2015175307A1 (en)	2014-05-16	2015-11-19	Janssen Biotech, Inc.	Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10465188B2 (en)	2014-08-22	2019-11-05	Auckland Uniservices Limited	Channel modulators
HK1254740A1 (zh)	2015-11-30	2019-07-26	Kadimastem Ltd.	分化和纯化胰腺内分泌细胞的方法
AU2017219254B2 (en) *	2016-02-17	2019-12-12	Novartis Ag	TGFbeta 2 antibodies
US10420803B2 (en)	2016-04-14	2019-09-24	Janssen Biotech, Inc.	Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
JP7531887B2 (ja) *	2020-07-31	2024-08-13	学校法人関西医科大学	ＴＧＦ－βを含む組織の線維化抑制剤
AU2021327376A1 (en)	2020-08-21	2023-04-20	University Of Miami	Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP4511045A1 (en)	2022-04-19	2025-02-26	University of Miami	Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155214A (en) *	1984-03-05	1992-10-13	The Salk Institute For Biological Studies	Basic fibroblast growth factor
GB8823649D0 (en) *	1988-10-07	1988-11-16	Geistlich Soehne Ag	Chemical compounds
IE61346B1 (en)	1988-11-02	1994-11-02	Genentech Inc	A permeable material to fit around the teeth or gums of a mammal
GB8927546D0 (en)	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
WO1991010727A1 (en) *	1990-01-22	1991-07-25	La Jolla Cancer Research Foundation	Inhibitors of cell regulatory factors
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing

1992
- 1992-03-28 GB GB929206861A patent/GB9206861D0/en active Pending
1993
- 1993-03-22 ES ES93906723T patent/ES2189790T3/es not_active Expired - Lifetime
- 1993-03-22 US US08/307,640 patent/US6331298B1/en not_active Expired - Fee Related
- 1993-03-22 BR BR9306226A patent/BR9306226A/pt not_active Application Discontinuation
- 1993-03-22 AT AT93906723T patent/ATE230605T1/de not_active IP Right Cessation
- 1993-03-22 NZ NZ249937A patent/NZ249937A/en not_active IP Right Cessation
- 1993-03-22 AU AU37623/93A patent/AU673161B2/en not_active Ceased
- 1993-03-22 JP JP51719393A patent/JP3919212B2/ja not_active Expired - Fee Related
- 1993-03-22 EP EP93906723A patent/EP0646012B1/en not_active Expired - Lifetime
- 1993-03-22 PT PT93906723T patent/PT646012E/pt unknown
- 1993-03-22 HU HU9402771A patent/HUT68905A/hu unknown
- 1993-03-22 DE DE69332624T patent/DE69332624T2/de not_active Expired - Lifetime
- 1993-03-22 CA CA002131383A patent/CA2131383C/en not_active Expired - Lifetime
- 1993-03-22 RU RU94042387/14A patent/RU94042387A/ru unknown
- 1993-03-22 CZ CZ942366A patent/CZ236694A3/cs unknown
- 1993-03-22 SK SK1168-94A patent/SK116894A3/sk unknown
- 1993-03-22 WO PCT/GB1993/000586 patent/WO1993019769A1/en not_active Ceased
- 1993-03-22 DK DK93906723T patent/DK0646012T3/da active
1994
- 1994-09-16 NO NO943466A patent/NO943466D0/no unknown
2005
- 2005-05-11 JP JP2005138819A patent/JP2005290009A/ja active Pending

Also Published As

Publication number	Publication date
HUT68905A (en)	1995-08-28
JP2005290009A (ja)	2005-10-20
ATE230605T1 (de)	2003-01-15
CZ236694A3 (en)	1995-04-12
DE69332624D1 (de)	2003-02-13
CA2131383C (en)	2002-07-16
GB9206861D0 (en)	1992-05-13
AU673161B2 (en)	1996-10-31
EP0646012B1 (en)	2003-01-08
NZ249937A (en)	1996-09-25
NO943466L (no)	1994-09-16
DE69332624T2 (de)	2003-10-02
JPH07505378A (ja)	1995-06-15
AU3762393A (en)	1993-11-08
NO943466D0 (no)	1994-09-16
US6331298B1 (en)	2001-12-18
JP3919212B2 (ja)	2007-05-23
WO1993019769A1 (en)	1993-10-14
DK0646012T3 (da)	2003-03-03
EP0646012A1 (en)	1995-04-05
RU94042387A (ru)	1996-11-10
ES2189790T3 (es)	2003-07-16
HU9402771D0 (en)	1995-01-30
PT646012E (pt)	2003-03-31
BR9306226A (pt)	1996-12-03
CA2131383A1 (en)	1993-10-14

Publication	Publication Date	Title
SK116894A3 (en)	1995-02-08	Mixture for treatment of fibrotic disordes
ES2136618T5 (es)	2007-10-16	Curacion de heridas.
EP1107791B1 (en)	2007-05-30	Hydrogel compositions for the controlled release administration of growth factors
DE69807710T2 (de)	2003-06-05	Verwendung von Latenz Assoziierten Peptiden in der Herstellung eines Medikaments zur Verbesserung der Wundheilung.
EP3272357A1 (de)	2018-01-24	Behandlung inflammatorischer krankheiten
SK281461B6 (sk)	2001-04-09	Kolagénový prípravok na riadené uvoľňovanie účinných látok
US7713933B2 (en)	2010-05-11	Pharmaceutical composition containing an activin or inhibin stimulator
KR20080031394A (ko)	2008-04-08	Ｔｇｆ-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
RU2248216C2 (ru)	2005-03-20	Композиция и способ увеличения количества стволовых клеток и/или гематопоэтических клеток-предшественников в циркуляции в периферической крови млекопитающих
CN1814279A (zh)	2006-08-09	重组人碱性成纤维细胞生长因子凝胶剂及其制备方法
US6623732B1 (en)	2003-09-23	Pharmaceutical formulation for nasal administration
EP2227246A1 (de)	2010-09-15	Behandlung von fibrosen und lebererkrankungen
JP5860406B2 (ja)	2016-02-16	徐放性医薬組成物
EP2737895A1 (en)	2014-06-04	Microparticles with EGF, method of preparation and use
JP2002528384A (ja)	2002-09-03	ペントキシフィリン及び抗サイトカインベースの組成物
EP4736879A1 (en)	2026-05-06	Sustained-release analgesic pharmaceutical composition, method for preparing same, and use thereof
US20050025743A1 (en)	2005-02-03	Method of preventing adhesions wtih ifn-upsilon
JP2688733B2 (ja)	1997-12-10	消化管粘膜障害の予防及び治療剤
AU2021394748A1 (en)	2023-06-08	Compositions and methods for treating wounds
WO2002072016A2 (en)	2002-09-19	Method of preventing adhesions with ifn-¿y?